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The 100,000 Genomes Project is a unique, national programme combining research 
and transformation of clinical care, by undertaking Whole Genome Sequencing 
(WGS) in patients with rare diseases and cancer. Made possible by technological 
advances in next generation sequencing1 and falling costs, this project aims to find 
the genes which cause a patient’s rare disease and identify genetic changes which 
occur in the tumour of a child or adult with cancer, to understand the mechanism of 
disease and develop therapies to personalise treatment. Patients are recruited 
through the NHS and their medical course is tracked for life through their NHS 
number with results fed back through routine NHS services. It will also lay the 
foundations for a new ‘genomic medicine’ service for the NHS.2  The project is 
coordinated by Genomics England, with participants enrolled through one of 
thirteen NHS Genomic Medicine Centres (GMCs) (Figure 1), covering all of England. 
Unlike genome projects in other countries3 that have yielded information on variants 
associated with common diseases and ancestry, the scale of the 100,000 Genomes 
Project is much greater. The ability to track long-term outcomes through the 
patients’ NHS number provides a unique opportunity to link genomic and phenotypic 
data to hospital admissions (via Hospital Episode Statistics) as well as lifelong  
response to interventions and treatments.  
 
 
Which children are eligible and how to refer? 
Many children with a rare disease but no known underlying cause are eligible. A local 
clinical geneticist4 or NHS Genomic Medicine Centre can advise on eligibility and 
recruitment. A detailed list and contact details can be found on the Genomics 
England website.5 Children with cancer who are undergoing biopsy or surgery are 
also eligible, with tumour and germline DNA sequenced in order to determine how 
the tumour arose and to target therapies. The Rare Diseases stream requires 
recruitment of several family members, usually the affected child and both parents, 
to facilitate interpretation of sequencing results and enable rapid exclusion of 
inherited non-pathogenic variants.       
 
Who will benefit?  
The main beneficiaries are children with rare diseases and their families as 
exemplified by the experience of one family who received a result recently (see 
box).6 Receiving a diagnosis not only puts an end to the ‘diagnostic odyssey’ and 
potentially allows targeted treatment, but enables reproductive planning and 
opportunities to make contact with other families whose children have similar 
problems7.  
 
Unaffected family members may also benefit. During WGS many variants beyond 
those directly responsible for the primary condition can be identified. Specific 
‘secondary’ findings can be fed back to adult participants,  including information 
about conditions for which treatment or screening can be offered to detect disease 
at an early stage, e.g. cancer predisposition genes and hypercholesterolaemia. 
Couples may also consent to receiving ‘reproductive findings’; for example if both 
parents are identified as carriers for cystic fibrosis, they may opt in to having this 
information. Children will be re-consented when they are 16 years and can request 
details of secondary findings then. 
 
This study will also stimulate biomedical research. Where a novel genetic cause of a 
rare disease is identified, validation and investigation to determine the disease 
mechanism is required. Where no obvious cause is found, further investigation may 
identify more subtle pathogenic findings. To facilitate this research groupings called 
‘Genomics England Clinical Interpretation Partnerships (GeCIPs)’ have been 
established; GeCIPs may be disease-specific or cross-cutting, to include ethics, social 
science research or population genomics. Commercial collaborations to develop new 
therapies and diagnostics are being established with several large pharmaceutical 
and biotechnology companies forming the GENE consortium8. For both commercial 
and academic partners data security is high with all analysis performed in the secure 
data centre, sitting behind the NHS firewall using anonymised patient data.  
 
What is the impact on paediatrics? 
The impact on paediatrics will be profound. Diagnosis and implementation of 
targeted treatment for children will become more efficient.  However interpretation 
of findings from WGS requires multidisciplinary team efforts involving clinicians, 
clinical scientists and bioinformaticians, so healthcare professionals will need to 
work together to interpret and exploit this genomic information. Genomic medicine 
will become increasingly established in clinical practice, but the manpower and skills 
required cannot be met within current clinical genetics services. The 100,000 
Genomes Project will become a training ground to establish patterns of working that 
include general and specialist paediatricians working together with clinical scientists. 
We need to train a new generation of healthcare professionals in genomic medicine, 
and existing clinicians need support as they come to grips with genomic medicine.  
Primary and secondary findings from WGS will need to be communicated to patients 
and families in a manner that is effective, appropriate and achievable. Health 
Education England is leading the delivery of education in genomics across the 
healthcare sector as part of the 100,000 Genomes project, offering a wide range of 
courses from a Masters in Genomic Medicine and CPD modules to on-line courses 
and brief aids to understanding all aspects of WGS.9  
 
Conclusions  
Technical challenges of WGS are being overcome, but ethical ones remain. What 
findings should be returned?  How to ensure patients give informed consent? Should 
results be reviewed longitudinally as knowledge improves? If so how?  Maybe the 
biggest immediate challenge is educating our workforce to deliver this exciting new 
technology. Changes to clinical practice will be far-reaching. More than ever we will 
need to work in multidisciplinary teams to enable accurate diagnosis and deliver 
appropriate therapy. These are exciting times, both for patients who are recipients 
of this new technology, but also for health professionals using it as part of their 
clinical armamentarium. 
 
Earlier this year the parents of the first two children to receive feedback from the 
100,000 Genomes Pilot study spoke publically about the impact of finally receiving a 
diagnosis (See box). These families and their healthcare teams had been struggling 
for years to identify the cause of their child’s problems.  The profound and positive 
effect this had on the families was summed up by one mother “When they said that 
they’d found something it was one of the biggest days of my life.”  
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Jessica’s Story 
 
When Jessica was born, everything seemed fine but by the time she was a year old she 
was behind on all her milestones and at 13 months old she had the first of many 
seizures. After many invasive tests Jessica’s parents were told that she had an 
undiagnosed condition. Her mother said: 
"It’s the not knowing that I found really difficult. We spent hundreds of hours 
researching online and wondering ‘is it this terrible syndrome; is it that terrible 
syndrome?’" 
They then heard about the 100,000 Genomes project and consented to take part in the 
pilot study. Blood was taken from both Jessica and her parents so that changes in 
Jessica’s genes could be compared with her parents’ genomes. The sequencing results 
showed that Jessica had GLUT1 Deficiency Syndrome. At a public meeting of NHS 
Genomic Medicine Centre staff her parents described some of the benefits the result 
had brought:  
"Now that we have this diagnosis there are things that we can do differently almost 
straight away. Her condition is one that has a high chance of improvement on a 
special diet, which means that her medication dose is likely to decrease and her 
epilepsy may be more easily controlled. Hopefully she might have better balance so 
she can be more stable and walk more.!” 
"A diagnosis also means that we can link up with other families who are in the same 
boat and can offer support. The condition is still quite rare but there are definitely 
other children out there who have it. I’m really looking forward to saying ‘we are one 
of you; we have this problem too!’ 
"The results are also going to be very useful for family planning. If we had had 
another child before, we didn’t know if they would certainly be affected by the same 
condition or if there was only a small chance. I think we can now say that there is 
only a tiny chance.” 
"More than anything the outcome of the project has taken the uncertainty out for us 
and the worry of not knowing what was wrong. It has allowed us to feel like we can 
take control of things and make positive changes for Jessica.”  
"It may also open doors to other research projects that we can to go on. These could 
be more specific to her condition and we are hopeful that they could one day find a 
cure." 
 
 
  
 
  
Figure. 1 Schema showing pathway from patient recruitment to results. Note the need for interaction 
between clinicians, scientists and geneticists working in multidisciplinary teams to deliver this new 
genomic medicine service. More detailed information can be found on the Genomics England website2 
(GMC – Genomics Medicine Centre; GeL – Genomics England; MDT – multidisciplinary team meeting 
including clinical scientists, clinical geneticists and referring clinicians) 
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